A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Clinical trial NCT03222310 · COMPLETED

Trial details

NCT number: NCT03222310
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Volunteers

Start date: 2017-07-18
Primary completion: 2017-09-06
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.